Not long at all...I believe it could complete within the quarter it commences in or beginning of the following quarter would announce completion. ECTE hopes to have a "soft" product launch this year. The words spoken are since they have until September to regain compliance hopefully with all the catalysts forthcoming a R/S won't be necessary.
Notice is hereby given that the 2013 Annual Meeting of Stockholders (the “Annual Meeting”) of Echo Therapeutics, Inc., a Delaware corporation (the “Company”), will be held at 10:00 a.m., local time, on May 22, 2013, at the Company’s offices located at 10 Forge Parkway, Franklin, Massachusetts 02038, to consider and act upon the following proposals:
1. To elect a Class II and a Class III director to the Company’s Board of Directors;
2. To approve an amendment to our Certificate of Incorporation, as amended, to effect a reverse stock split by a ratio of not less than 1-for-2 and not more than 1-for-10 at any time prior to December 31, 2013, with the exact ratio to be set within this range by the Company’s Board of Directors in its sole discretion;
3. To approve an amendment to our 2008 Equity Incentive Plan to fix the aggregate number of shares of our common stock subject to the 2008 Plan at 10,000,000 shares subject to the approval of Proposal 2 relating to the reverse stock split and after giving effect to the reverse stock split;
4. To approve an amendment to our 2008 Equity Incentive Plan to fix the limitation on awards of stock options during any twelve-month period to any one participant, which we refer to as the “Section 162(m) limitation,” at 425,000 shares, subject to the approval of Proposal 2 relating to the reverse stock split and after giving effect to the reverse stock split;
5. To ratify the appointment of Wolf & Company, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2013; and
6. To transact such other business, if any, as may properly come before the meeting or any adjournments thereof.
The Board of Directors of the Company has no knowledge of any other business to be transacted at the Annual Meeting. Only holders of record of the Company’s common stock, $.01 par value per share, and holders of the Company’s Series D Convertible Preferred Stock, $.01 par value per share, at the close of business on April 11, 2013 are entitled to notice of and to vote at the Annual Meeting. All stockholders are cordially invited to attend the Annual Meeting in person.
To ensure your representation at the Annual Meeting, you are urged to vote by (i) marking, signing and dating your proxy card and returning it in the postage-prepaid envelope, (ii) calling the toll-free number on your proxy card, (iii) visiting the website listed on your proxy card, or (iv) attending the Annual Meeting and voting in person. You may revoke your proxy in the manner described in the Proxy Statement at any time before it has been voted at the Annual Meeting. Any stockholder attending the Annual Meeting may vote in person even if he or she has returned a proxy.
NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON MAY 22, 2013: THE ANNUAL REPORT AND PROXY STATEMENT ARE ALSO AVAILABLE ONLINE AT WWW.PROXYCONNECT.COM/ECHO.
By Order of the Board of Directors,
Kimberly A. Burke, Secretary Philadelphia, Pennsylvania
Market Data 
Markets 
AI
